Erasca Announces Pricing of Upsized Public Offering of Common Stock

Rhea-AI Summary

Erasca (Nasdaq: ERAS) priced an upsized public offering of 22,500,000 shares of common stock at $10.00 per share, generating expected gross proceeds of $225.0 million. The company granted the underwriters a 30‑day option to purchase up to an additional 3,375,000 shares at the offering price, less underwriting discounts and commissions.

The offering is expected to close on January 23, 2026, subject to customary closing conditions. Net proceeds, together with existing cash and securities, are intended to fund research and development of product candidates, other development programs, and for working capital and general corporate purposes.

Positive

• Offering size of 22,500,000 shares
• Gross proceeds expected at $225.0 million
• Underwriter option for 3,375,000 additional shares

Negative

• Potential dilution from issuance of 22,500,000 shares
• Net proceeds reduced by underwriting discounts and commissions

News Market Reaction

+2.45%

10 alerts

+2.45% News Effect

+16.1% Peak Tracked

-3.8% Trough Tracked

+$72M Valuation Impact

$3.03B Market Cap

0.3x Rel. Volume

On the day this news was published, ERAS gained 2.45%, reflecting a moderate positive market reaction. Argus tracked a peak move of +16.1% during that session. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $72M to the company's valuation, bringing the market cap to $3.03B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Primary shares offered: 22,500,000 shares Offering price: $10.00 per share Gross proceeds: $225.0 million +5 more

8 metrics

Primary shares offered 22,500,000 shares Upsized underwritten public offering of common stock

Offering price $10.00 per share Public offering price for common stock

Gross proceeds $225.0 million Expected gross proceeds before fees and expenses

Underwriters’ option shares 3,375,000 shares 30-day option for additional shares at offering price

Option period 30 days Underwriters’ option to purchase additional shares

Shelf effective date August 22, 2025 Form S-3 shelf registration declared effective by SEC

Shelf capacity $500,000,000 Total securities capacity under S-3 shelf registration

ATM program size $200,000,000 Common stock ATM included within shelf amount with Jefferies LLC

Market Reality Check

Price: $12.01 Vol: Volume 8,742,244 vs 20-da...

normal vol

$12.01 Last Close

Volume Volume 8,742,244 vs 20-day avg 8,171,106 (relative volume 1.07) ahead of this offering news. normal

Technical Pre-offering, ERAS traded at $10.05, well above its $2.25 200-day MA, near its 52-week high of $10.42 and -3.55% below that peak.

Peers on Argus

Sector peers (ALMS, ITOS, OLMA, PRTA, ZVRA) showed modest mixed gains, while mom...

1 Up

Sector peers (ALMS, ITOS, OLMA, PRTA, ZVRA) showed modest mixed gains, while momentum scanners only flagged CRVS (+4.74%) with no news, indicating ERAS’s offering is a stock-specific event rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 20 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	Equity offering plan	Negative	+2.0%	Proposed $150M common stock offering under existing shelf registration.
Jan 12	Clinical data update	Positive	-7.8%	Early Phase 1 data for ERAS-0015 with partial responses and no DLTs.
Jan 06	Conference presentation	Neutral	+4.0%	Announcement of presentation and webcast at J.P. Morgan Healthcare Conference.
Nov 25	Conference appearance	Neutral	+6.2%	Planned participation in Evercore Healthcare Conference with webcast access.
Nov 12	Earnings and pipeline	Positive	+12.3%	Q3 2025 results, strong cash of $362.4M and runway into H2 2028.

Pattern Detected

Recent news reactions have been mixed: a prior offering and conferences saw positive moves, while promising clinical data sold off and earnings rallied strongly, indicating inconsistent trading responses to both financing and pipeline milestones.

Recent Company History

Over the last few months, Erasca has combined clinical, financing, and investor-relations milestones. An earlier offering announcement on Jan 20, 2026 saw a +1.98% move. Early Phase 1 RAS-program data on Jan 12, 2026 led to a -7.84% reaction despite promising signals. Conference participation in November 2025 and January 2026 drew positive moves of 6.23% and 4.01%. Q3 2025 results on Nov 12, 2025, highlighting $362.4M in cash and runway into H2 2028, were followed by a strong +12.29% gain. Today’s upsized offering pricing builds directly on the Jan 20 financing proposal.

Regulatory & Risk Context

Active S-3 Shelf · $500,000,000

Shelf Active

Active S-3 Shelf Registration 2025-08-12

$500,000,000 registered capacity

Erasca has an effective Form S-3 shelf filed on Aug 12, 2025, allowing issuance of up to $500,000,000 in securities, including a $200,000,000 ATM program. The current underwritten offering, documented by a 424B5 usage on Jan 20, 2026, taps into this capacity and may contribute to shareholder dilution, though it also strengthens the company’s funding for R&D and corporate purposes.

Market Pulse Summary

This announcement prices an upsized equity offering of 22,500,000 shares at $10.00, for expected gro...

Analysis

This announcement prices an upsized equity offering of 22,500,000 shares at $10.00, for expected gross proceeds of $225.0 million, under an existing Form S-3 shelf declared effective on August 22, 2025. The deal follows a recently proposed $150.0 million offering and sits alongside an at-the-market program within a $500,000,000 shelf. Investors may focus on how added capital supports R&D timelines, past cash runway into H2 2028, and the balance between dilution and funding flexibility.

Key Terms

shelf registration statement, form s-3, base prospectus, prospectus supplement, +4 more

8 terms

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3, including a base prospectus"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"pursuant to a shelf registration statement on Form S-3, including a base prospectus"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

base prospectus regulatory

"on Form S-3, including a base prospectus, that was previously filed with the"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

prospectus supplement regulatory

"A preliminary prospectus supplement relating to this offering has been filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

underwriters financial

"Erasca has granted the underwriters a 30-day option to purchase"

Underwriters are financial professionals or institutions that help companies raise money by selling new securities, such as stocks or bonds, to investors. They assess the risk and determine the price at which these securities should be sold, acting like a bridge between the company and the investors. Their role helps ensure that the company raises the needed funds while providing investors with options that reflect the level of risk involved.

public offering financial

"announced the pricing of an upsized public offering of 22,500,000 shares"

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

nasdaq financial

"Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

securities and exchange commission (sec) regulatory

"previously filed with the Securities and Exchange Commission (SEC) and was"

A U.S. federal agency that oversees the stock and securities markets, requiring public companies and brokers to register and share accurate financial information so investors can see the facts. It enforces rules, investigates fraud and can pause or change market activity; think of it as a referee whose decisions and investigations affect investor confidence, legal risk and the value of traded securities.

AI-generated analysis. Not financial advice.

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $225.0 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 3,375,000 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on January 23, 2026, subject to the satisfaction of customary closing conditions.

Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.

J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering.

The securities described above are being offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) and was declared effective on August 22, 2025.

A preliminary prospectus supplement relating to this offering has been filed with the SEC and a final prospectus supplement relating to this offering will be filed with the SEC. The offering may be made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Forward Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the expected closing of the offering and the anticipated use of proceeds therefrom. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

FAQ

How many shares did Erasca (ERAS) offer in the January 2026 upsized public offering?

Erasca offered 22,500,000 shares of common stock in the upsized offering.

What price per share did Erasca (ERAS) set for the January 2026 offering?

The public offering price was set at $10.00 per share.

How much gross capital will Erasca (ERAS) raise from the January 2026 offering?

Gross proceeds to Erasca are expected to be $225.0 million before fees and expenses.

Does Erasca (ERAS) allow underwriters to buy more shares after the January 2026 offering?

Yes, underwriters have a 30‑day option to purchase up to 3,375,000 additional shares.

When is the Erasca (ERAS) offering expected to close?

The offering is expected to close on January 23, 2026, subject to customary closing conditions.

What will Erasca (ERAS) use the net proceeds from the January 2026 offering for?

Net proceeds are intended to fund research and development, other development programs, working capital, and general corporate purposes.